

Remarks


In response to Office Action mailed June 19, 2007, Applicants have amended claims 2 and 3 to correct clearly discernable grammatical errors (addition of semicolons between members of the list of compounds in claim 2, addition of "and" before the last member of that list in claim 2, and addition of a period at the end of claim 2), and to eliminate dependency (claim 3 now depends from claim 2 only). Claims 1 and 4-28 have been cancelled as claiming non-elected subject matter. Applicants expressly reserve the right to claim the subject matter of claims 1 and 4-28, as well as any other subject matter supported by the specification, at a later time.

Applicants have also included a request for a two (2) month extension of time for responding to the Office Action.

Lastly, Applicants submit herewith a Terminal Disclaimer of the pending claims 2 and 3 over copending and commonly owned U.S. Patent Application Serial No. 10/552,503. The Terminal Disclaimer moots the provisional double patenting rejection which is the only rejection made of the pending claims in the Office Action. Applicants thereby respectfully request a Notice of Allowance for the pending claims at the next opportunity.

Authorization is hereby provided to charge any required fees to Deposit Account No. 50-0912.

Respectfully submitted,
SALMAN et al.

By: 
George E. Heibel, PhD
Reg. No. 42,648

Date: November 19, 2007

Correspondence Address:
Ranbaxy Inc.
600 College Road East, Suite 2100
Princeton, NJ 08540
Telephone: (609) 720-5334
Facsimile: (609) 514-9779